Research Article

Chemotherapy Exposure and outcomes of Chronic Lymphoid Leukemia Patients

Josephina G Kuiper*, Patience Musingarimi, Christoph Tapprich, Fernie JA Penning-van Beest and Maren Gaudig

Published: 26 June, 2017 | Volume 2 - Issue 1 | Pages: 025-033

This study describes chemotherapy exposure, healthcare utilization, overall survival (OS) and progression-free survival (PFS) among patients diagnosed with chronic lymphoid leukemia (CLL). Newly diagnosed CLL patients who received chemotherapy were selected from the Eindhoven Cancer Registry between 1998-2011, linked on a patient-level to the PHARMO Database Network including data on in- and out-patient drug dispensings, hospitalizations and clinical laboratory measurements. Chemotherapy was classified in regimens of use based on chemotherapy combinations. OS and PFS were determined after diagnosis and after chemotherapy. Healthcare utilization was assessed in the year before diagnosis and in the year after chemotherapy.

In total, 125 CLL patients received chemotherapy: 52 patients (42%) started chemotherapy within 6 months and 73 patients (58%) started chemotherapy ≥6 months after diagnosis. Mean (±SD) age was 67(±10) years and 68% was male. About 50% had one treatment line and about 25% two lines of treatment. Chlorambucil was the most common type of first line chemotherapy. Prior diagnosis, 44% were hospitalized for any cause and 94% had at least one drug dispensing. After chemotherapy, this was 43% and 98%, respectively. One-year survival rate after diagnosis was 94%. Median PFS after first treatment line was 17 months for patients starting within 6 months and 27 months for patients starting ≥6 months after diagnosis. In conclusion, most CLL patients receiving chemotherapy were treated with chlorambucil. One-year after initial diagnosis, 94% were still alive. Median PFS after first line chemotherapy ranged from 17 to 27 months, depending on the timing of chemotherapy.

Read Full Article HTML DOI: 10.29328/journal.jcicm.1001006 Cite this Article Read Full Article PDF


Chronic lymphoid leukemia; Chemotherapy exposure; Healthcare utilization; Survival


  1. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008; 371: 1017-1029. Ref.: https://goo.gl/BfTm5Q
  2. Hoeller S, Zhou Y, Kanagal-Shamanna R, Xu-Monette ZY, Hoehn D, et al. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol. 2013; 44: 110-121. Ref.: https://goo.gl/J5UL6L
  3. Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007; 139: 809-819. Ref.: https://goo.gl/Smy7fF
  4. Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 2013; 88: 803-816. Ref.: https://goo.gl/YUDyiu
  5. Van den Broek EC, Kater AP, van de Schans SA, Karim-Kos HE, Janssen-Heijnen ML, et al. Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival. 1989-2008. Eur J Cancer. 2012; 48: 889-895. Ref.: https://goo.gl/hm2H7y
  6. Sant M, Allemani C, Tereanu C, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010; 116: 3724-3734. Ref.: https://goo.gl/PH8YGM
  7. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111: 5446-5456. Ref.: https://goo.gl/cDQHGV
  8. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007; 25: 5616-5623. Ref.: https://goo.gl/vWMZZh
  9. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 1750-1757. Ref.: https://goo.gl/uMa8kv
  10. Woods B, Hawkins N, Dunlop W, O'Toole A, Bramham-Jones S. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. Value Health. 2012; 15: 759-770. Ref.: https://goo.gl/ZGnyWi
  11. Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol. 2014; 32: 1236-1241. Ref.: https://goo.gl/p9S6fG
  12. Hovon CLWP. Richtlijnen Diagnostiek en Behandeling Chronische Lymfatische Leukemie/Small Lymphocytic Lymphoma (CLL/SLL) en Hairy Cell Leukemie (HCL). 2015.
  13. Van Herk-Sukel MP, Van de Poll-Franse LV, Lemmens VE, Vreugdenhil G, Pruijt JF, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer. 2010; 46: 395-404. Ref.: https://goo.gl/UoSvv8
  14. Netherlands Comprehensive Cancer Organisation. [www.netherlandscancerregistry.nl]
  15. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011; 22: 50-54. Ref.: https://goo.gl/jvNg7K
  16. Group CTC. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999; 91: 861-868. Ref.: https://goo.gl/n7MGdY
  17. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010. 376: 1164-1174. Ref.: https://goo.gl/zvCCsF
  18. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370: 1101-1110. Ref.: https://goo.gl/SwofbB
  19. European public assessment report (EPAR) for Imbruvica. 2015.
  20. Brown JR. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 2013; 8: 1-6. Ref.: https://goo.gl/Y2W993
  21. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371: 213-223. Ref.: https://goo.gl/oam8


Figure 1

Figure 1

Figure 1

Figure 2

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More